A Randomised, Single-centre, Double-blind, Two-period Cross-over, Multiple Dose Trial Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 12 Nov 2016 According to a Novo Nordisk media release, results from the study were presented at the 16th Annual Diabetes Technology Meeting.
- 12 Nov 2016 Results published in a Novo Nordisk media release.
- 02 May 2016 Status changed from active, no longer recruiting to completed.